I den endelige vurderingsrapport (dateret den 14. 2. 2005) blev den af referencemedlemsstaten foreslåede indikation begrænset til "Reduktion af risiko for recidiv af MI hos patienter med tidligere MI" i betragtning af, at risikoreduktion kun var påvist for komponenten "ikke dødelig MI" i det primære endepunkt, og at virkningen af perindopril kun var klart godtgjort hos patienter med tidligere MI.
In the Final Assessment report (dated on 14.02.2005), the indication proposed by the RMS was restricted to “ Reduction of risk of recurrent MI in patients with a history of MI” considering that the risk reduction was only demonstrated on the “ non fatal MI” component of the primary endpoint and that the effect of perindopril was only clearly established in patients with previous MI.